期刊文献+

肾移植术后合并急性心梗患者的药学监护 被引量:1

Postoperative pharmaceutical care of patients with acute myocardial infarction complication after renal transplantation
在线阅读 下载PDF
导出
摘要 目的探讨临床药师对特殊生理状态患者的药学监护方法及角度,从而为临床合理用药提供参考。方法对1例肾移植术后14年合并急性非ST段抬高心肌梗死患者从药物选择、相互作用、代谢、排泄等方面进行全程的药学监护,为医师的药物治疗提供合理化用药建议。结果通过本次药学监护,对处于特殊生理状态同时使用抗免疫排斥方案的患者的用药方案有了新的认识,在药师的积极参与下患者平安出院。结论临床药师参与临床药物治疗过程,为患者制订个体化的治疗方案,可以有效保障患者用药安全,提高个体化水平。 Objective To provide reference for clinical rational use of drugs through the investigation of the methods and points of a pharmaceutical care about a special physiological state patient.Methods The clinical pharmacist offer the entire pharmaceutical care including drug selection,interaction,metabolism,excretion to the patients who suffered from acute non-ST-segment elevation myocardial infarction with a kidney transplantation 14 years ago,for the rational drug using recommendations of the physician medication.Results With the active participation of the pharmacists,the patients safely discharged from hospital,and we obtained a newunderstanding of the drug using plan for the patients in a special physiological state who were under the anti-immune rejection treatment from the pharmaceutical care.Conclusion The results indicate that the clinical pharmacists participat in clinical drug treatment process for patients to develop individualized treatment programs which can be effective in protecting the safety of the drug use of patients to improve the individual drug using level.
机构地区 沈阳军区总医院
出处 《实用药物与临床》 CAS 2013年第9期836-838,共3页 Practical Pharmacy and Clinical Remedies
关键词 急性心梗 肾移植术后 临床药师 药学监护 Acute myocardial infarction/AMI Kidney transplant Clinical pharmacist Pharmaceutical care
  • 相关文献

参考文献5

二级参考文献42

  • 1党书毅,詹中群,王玮,王崇全,马红梅,王俊峰,方志成.选择性冠状动脉造影并发心室颤动的原因与对策[J].郧阳医学院学报,2004,23(5):293-294. 被引量:4
  • 2MeCullough PA.Contrast-induced acute kidney injury.J Am Coll Cardial,2008,51:1419-1428.
  • 3Bartorelli AL,Marenzi G.Contrast-induced nephropatby.J Interv Cardiol,2008,21:74-85.
  • 4Marenzi G,Assanelli E,Marana L,et al.N-Acetylcysteine and contrast-induced ncphropathy in primary angioplasty.N Engl J Med,2006,354:2773-2782.
  • 5Spargias K,Alexopoulos E,Kyrzopoulos S,et al.Ascorhic acid prevents contrast-mediated nephropathy in patients with renal dysfunction undergoing coronary angiography or intervention.Circulation,2004,110:2837-2842.
  • 6Miida T,Seino U,Miyazaki O,et al.Probucol markedly reduced HDL phospholipids and elevated pre betall-HDL without delayed conversion into alpha-migrating HDL:Putative role of angiopoietinlike protein 3 in probucol-induced HDL remodeling.Atherosclerosis,2008,200:329-335.
  • 7Barrett BJ,Parfrey PS.Preventing nephropathy induced by contrast medium.N Engl J Med,2006,354:1853-1855.
  • 8McCullough PA,Adam A,Beckcr CR,et al.Epidemiology and prognostic implications of contrast-induced nephropathy.Am J Cardiol,2006,98:5K-13K.
  • 9Dussol B,Morange S,Loundoun A,et al.A randomized trail of saline hydration to prevent contrast nephropathy in chronic renal failure patients.Nephrol Dial Transplant,2006,21:2120-2126.
  • 10Patti G,Nusca A,Chello M,et ai.Usefulness of statin pretreatment to prevent contrast-induced nephropathy and to improve long-term outcome in patients undergoing percutaneous coronary intervention.Am J Cardiol,2008,101:279-285.

共引文献554

同被引文献7

二级引证文献11

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部